Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
This article was originally published in The Pink Sheet Daily
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
You may also be interested in...
In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.
The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.
Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.